EndocrineToday.com blogger discusses treating osteoporosis

Kleerekoper, Michael
March 2008
Endocrine Today;3/10/2008, Vol. 6 Issue 4, p5
The article discusses treatment of osteoporosis in a 44-year-old Filipino woman, whose gynecologist recommended that she have a bone density study. The author presents the history of the illness of the patient. The author also states that most of the published guidelines advised that bone density study should not be done in healthy women before the age of 65 and to women without a history or family history of hip fracture or smoking. It notes that two-dimensional technology DEXA has less change in slender women particularly in the spine.


Related Articles

  • Emerging Therapies for Osteoporosis. McClung, Michael R. // Endocrinology & Metabolism;Dec2015, Vol. 30 Issue 4, p429 

    Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed....

  • Denosumab: A new injectable treatment for postmenopausal osteoporosis. Whelan, Anne Marie; Raman-Wilms, Lalitha // Canadian Pharmacists Journal;Mar/Apr2011, Vol. 144 Issue 2, p72 

    The article presents a study which determines the efficacy of the injectable denosumab for the treatment of postmenopausal osteoporosis. The researchers have examined the safety and effect of denosumab on bone mineral density (BMD) in the management of postmenopausal osteoporosis. The study...

  • New practice guideline for osteoporosis.  // Neurology Alert;Nov2008 Pharmacology Watch, p2 

    The article reports on the Clinical Practice Guideline issued by the American College of Physicians in November 2008 concerning the pharmacologic treatment of patients with low bone density or osteoporosis. It references a study published in a 2008 issue of the "Annals of Internal Medicine." As...

  • Dietary Calcium Intake and Socioeconomic Status Are Associated with Bone Mineral Density in Postmenopausal Women. Tajik, Esra; Shariff, Zalilah Mohd; Esfehani, Ali Jafarzadeh; Mun, Chan Yoke; Ebrahimi, Fatemeh // World Applied Sciences Journal;2014, Vol. 31 Issue 2, p244 

    Osteoporosis is characterized by a decrease in the strength and density of bone and is a major cause of premature death in elderly. This cross-sectional study aimed to determine the relationship between bone mineral density and calcium intake and socioeconomic factors among postmenopausal women...

  • Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Kastelan, Darko; Lozo, Petar; Stamenkovic, Doris; Miskic, Blazenka; Vlak, Tonko; Kolak, Zeljka; Milas Ahic, Jasminka; Altabas, Velimir; Crncevic Orlic, Zeljka; Korsic, Mirko // Clinical Rheumatology;Mar2009, Vol. 28 Issue 3, p321 

    The PROMO (preference for once monthly bisphosphonate) Study, conducted in seven hospital centres in Croatia between June 2007 and June 2008, was designed to analyse patient preference for weekly and monthly bisphosphonates in everyday clinical practice where the significant proportion of...

  • Clodronic Acid in the Treatment of Postmenopausal Osteoporosis. Tanakol, Refik; Yarman, Sema; Bayraktaroglu, Taner; Boztepe, Harika; Alagöl, Faruk // Clinical Drug Investigation;2007, Vol. 27 Issue 6, p419 

    BACKGROUND: Clodronic acid, a first-generation bisphosphonate, has been successfully used in the treatment of high bone turnover states, Paget’s disease and osteolytic bone metastases. However, controversies remain over its optimal dosage and method of administration in the...

  • EFFECT OF RISEDRONATE AND STRONTIUM THERAPY ON BONE MINERAL DENSITY IN POSTMENOPAUSAL OSTEOPOROSIS. Narula, Ramesh; Mujtaba, Tauseef; Iraqi, Aftab Ahmed; Singh, Somdutt // International Journal of Research in Ayurveda & Pharmacy;Jul/Aug2012, Vol. 3 Issue 4, p543 

    Clinical studies show that treatment with strontium ranelate which is comparatively a new oral agent leads to relatively larger increases in (Bone Mineral Density) BMD compared with alternative agents such as biphosphanates. The present study was designed to compare the effect of treatment with...

  • Stroncium ranelát nemá pÅ™i léčení osteoporózy osteoanabolické (duální) účinky. Štěpán, J. // Czech Rheumatology / Ceska Revmatologie;2014, Vol. 22 Issue 1, p18 

    The results of studies for approval for the treatment of osteoporosis in postmenopausal women and in men have demonstrated a significant increase in BMD at the lumbar spine and proximal femur and reduction in the relative risk of vertebral and non-vertebral fractures. Strontium deposited in bone...

  • Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Delmas, P. D.; Benhamou, C. L.; Man, Z.; Tlustochowicz, W.; Matzkin, E.; Eusebio, R.; Zanchetta, J.; Olszynski, W. P.; Recker, R. R.; McClung, M. R. // Osteoporosis International;Jul2008, Vol. 19 Issue 7, p1039 

    Postmenopausal women with osteoporosis received 75 mg risedronate on two consecutive days each month or 5 mg daily for 12 months. Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg twice monthly was effective and safe suggesting a new,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics